Home / Market News / $ZVRA

$ZVRA news and market catalysts

The 10 most recent market catalysts affecting $ZVRA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

10 catalysts 5 high impact 4 bullish 4 bearish Biotechnology
Nov 3, 2026 Corporate Catalyst Neutral Impact 85
Zevra Therapeutics Reports Third Quarter 2026 Financial Results
Zevra Therapeutics announced robust Q3 2026 financial results, with a 45% year-over-year increase in net revenue to $37.8 million, largely attributed to $34.0 million in MIPLYFFA s…
Oct 31, 2026 Corporate Catalyst Bullish Impact 65
Zevra Therapeutics, Inc. Stock 12-Month Price Target Raised to $25.25
The filing indicates that Zevra Therapeutics has received an increased 12-month price target of $25.25 from eight analysts, with a unanimous 'Buy' rating from nine analysts. This i…
Aug 25, 2026 Corporate Catalyst Neutral Impact 55
Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposium
Zevra Therapeutics is presenting long-term real-world data on its drug MIPLYFFA for Niemann-Pick disease type C at the SSIEM Annual Symposium. This is a positive development as it …
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Zevra Therapeutics shares are trading higher after Citizens raised its price target on the stock from $25 to $28.
The upgrade of Zevra Therapeutics' price target by Citizens from $25 to $28 is a significant positive catalyst for the stock. Analyst upgrades often lead to increased investor conf…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28
Citizens analyst Jason N. Butler has maintained a 'Market Outperform' rating on Zevra Therapeutics and raised the price target from $25 to $28. This action signals increased confid…
Aug 5, 2026 Corporate Catalyst Bullish Impact 65
Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical Development
Zevra Therapeutics disclosed that it enrolled four additional patients in its Phase 3 DiSCOVER trial for celiprolol during Q2 2026, bringing the total to 66 patients with three con…
Aug 5, 2026 Corporate Catalyst Bearish Impact 92
UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate
Zevra Therapeutics announced Q2 earnings that significantly surpassed analyst expectations for both adjusted EPS and sales. The company's sales grew by over 53% year-over-year, dem…
Aug 5, 2026 Corporate Catalyst Bearish Impact 92
Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate
Zevra Therapeutics (ZVRA) announced Q2 earnings per share of $0.14, significantly exceeding the analyst consensus of $0.11. Furthermore, the company's sales of $39.663 million comf…
Jul 24, 2026 Corporate Catalyst Bearish Impact 85
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C
Zevra Therapeutics (ZVRA) is experiencing a significant stock decline due to a negative opinion from the European Medicines Agency's CHMP regarding its drug arimoclomol for Niemann…
Jul 24, 2026 Corporate Catalyst Bearish Impact 95
Zevra Therapeutics shares are trading lower after the company announced the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a negative opinion regarding the Marketing Authorization Application for arimoclomol for the treatment of Niemann-Pick disease type C.
The negative opinion from the CHMP is a major setback for Zevra Therapeutics, as it directly impacts the potential market authorization and commercialization of arimoclomol in Euro…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.